According to the agreement, Shionogi and Shire will co-develop and co-market Intuniv (guanfacine) and Vyvanse (lisdexamfetamine) in Japan. In return, Shire will receive an upfront payment and royalties based on sales. Shionogi will also share development costs with Shire. The two aim to commercialize the drugs in 5-7 years. Vyvanse is currently marketed in the U.S., Canada and Brazil, and its 2010 sales grew to $634 million. Available in the U.S. since Nov. 2009, Intuniv sales reached $166 million in 2010. Shionogi is focusing on central nerve system disease and holds the Japanese rights to Cymbalta (duloxetine). (Click here for more – Japanese language
Shionogi To Co- Develop Shire ADHD Drugs In Japan
Shionogi has signed a licensing agreement with Irish firm Shire PLC to develop two drugs for attention deficit hyperactivity disorder.